S.Biomedics Co. Ltd.

S.Biomedics Co., Ltd. is a biopharmaceutical company focused on research and development of stem cell therapy products. Its pipeline includes TED-N and TED-A9, both in phase 1/2a clinical development for subacute spinal cord injury and Parkinson's disease respectively, along with FECS-Ad, FECS-DF, TED-R, CF-TED-N, and CF-FECS-DF for other indications. The company also provides testing services and owns platform technologies for developing cell therapy products, and has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. Founded in 2005, it is headquartered in Seoul, South Korea.